Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome

Journal Article · · Proc. Natl. Acad. Sci. U.S.A.; (United States)

The Philadelphia chromosome is the cytogenetic hallmark of human chronic myelogenous leukemia. RNA splicing joins sequences from a gene on chromosome 22 (BCR) across the translocation breakpoint to a portion of the ABL oncogene from chromosome 9, resulting in a chimeric protein (P210) that is an active tyrosine kinase. Although strongly correlated with this specific human neoplasm, and implicated as an oncogene by analogy to the gene product of the Abelson murine leukemia virus, the P210 gene had not been tested directly for oncogenic potential in hematopoietic cells. The authors have used a retroviral gene-transfer system to express P210 in mouse bone marrow cells. When infected bone marrow is plated under conditions for long-term culture of cells of the B-lymphoid lineage, cells expressing high amounts of P210 tyrosine kinase dominate the culture and rapidly lead to clonal outgrowths of immature lymphoid cells. Expression of P210 is growth-stimulatory but not sufficient for full oncogenic behavior. Some clonal lines progress toward a fully malignant phenotype as judged by increased cloning efficiency in agar suspension and frequency and rapidity of tumor induction in syngeneic mice. Such in vitro systems should be useful in evaluating the sequential and perhaps synergistic involvement of the P210 gene and other oncogenes as models for the progressive changes observed in human chronic myelogenous leukemia.

Research Organization:
Univ. of California, Los Angeles (USA)
OSTI ID:
7141786
Journal Information:
Proc. Natl. Acad. Sci. U.S.A.; (United States), Journal Name: Proc. Natl. Acad. Sci. U.S.A.; (United States) Vol. 84:18; ISSN PNASA
Country of Publication:
United States
Language:
English

Similar Records

BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias
Journal Article · Sun Mar 31 23:00:00 EST 1991 · Molecular and Cellular Biology; (United States) · OSTI ID:7176830

SGX393 inhibits the CML mutant Bcr-Abl[superscript T315I] and preempts in vitro resistance when combined with nilotinib or dasatinib
Journal Article · Mon Jan 11 23:00:00 EST 2010 · Proc. Natl. Acad. Sci. USA · OSTI ID:1007145

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Journal Article · Thu Oct 25 00:00:00 EDT 2012 · Cell · OSTI ID:1039450